Aardvark Therapeutics’ (AARD) “Neutral” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note released on Monday morning,Benzinga reports.

Other research analysts also recently issued research reports about the company. Royal Bank Of Canada reissued a “sector perform” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Thursday, September 24th. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Tuesday, September 29th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.12.

Aardvark Therapeutics Trading Down 4.0%

AARD opened at $3.88 on Monday. The stock’s fifty day simple moving average is $5.75 and its 200 day simple moving average is $5.29. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.60. The stock has a market cap of $84.89 million, a PE ratio of -1.21 and a beta of 3.80.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. Equities analysts forecast that Aardvark Therapeutics will post -3.17 earnings per share for the current year.

Insider Activity

In other news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the sale, the insider owned 35,475 shares of the company’s stock, valued at $183,760.50. This trade represents a 63.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AARD. BlackRock Inc. acquired a new position in shares of Aardvark Therapeutics during the second quarter valued at about $1,077,000. Susquehanna International Group LLP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at about $138,000. J. Goldman & Co LP bought a new stake in Aardvark Therapeutics in the 2nd quarter valued at about $233,000. Ieq Capital LLC bought a new stake in Aardvark Therapeutics in the 2nd quarter valued at about $221,000. Finally, Renaissance Technologies LLC bought a new stake in Aardvark Therapeutics in the 1st quarter valued at about $267,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.